FDA

Boehringer's Zongertinib ReceivesFDA Priority Review for the Treatment of HER2 (ERBB2)- NSCLC

Boehringer Ingelheim Pharmaceuticals, Inc.

Investment

Boehringer Ingelheim Invests Nearly $50 Million to Expand Plant in Puerto Rico

Boehringer Ingelheim

Clinical Data

New Data Reinforces Benefits of Spiolto® Respimat® in Improving Patient Outcomes

Boehringer Ingelheim

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Disease

Boehringer Ingelheim

Virtual Research

Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies

Boehringer Ingelheim

M&A

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform

Boehringer Ingelheim

Legal

AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim

AbbVie

Real World Data

Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors

Eli Lilly and Company

Partnership

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford Biomedica Announce New Partnership

Boehringer Ingelheim

Insulin

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Boehringer Ingelheim

Discovery Platform

Biomax Informatics Software Licensed by Global Pharma Company, Boehringer Ingelheim, to Build a Target Discovery Knowledge Platform

Biomax Informatics

Drug Development

Praxbind®, Specific Reversal Agent for Pradaxa®, Now Available in 3,200 Hospitals Nationwide

Boehringer Ingelheim

Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries

Boehringer Ingelheim

FDA Approval

FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa

Boehringer Ingelheim

Collaboration

Boehringer Ingelheim and Lilly Announce an Academic Collaboration with University of Oxford

Boehringer Ingelheim

Animal Health

LEUKOCARE and Boehringer Ingelheim Enter into a Long-Term Agreement in the Field of Animal Health

Boehringer Ingelheim

Immuno-Oncology

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership

Boehringer Ingelheim

Clinical Trials

Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine

Boehringer Ingelheim

Awareness

Boehringer Ingelheim and Minor League Baseball Team Up to Raise Awareness of Rare Lung Disease – IPF

Boehringer Ingelheim Pharmaceuticals, Inc.